THE SECOND APPLICATION FOR LISTING OF LIRAGLUTIDE INJECTION IN CHINA

Liraglutide is a human glucagon like peptide-1 (GLP-1) analog, which has 97% sequence homology with human GLP-1. The first original product was developed by Novo Nordisk
Nordisk, and was approved to control  blood sugar in adult type 2 diabetes patients.
Liraglutide not only effectively controls blood sugar, but also has cardiovascular protection and weight loss effects. Its weight loss indications have been approved by the US FDA.

Indications:

Liraglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Infliximab for Injection https://www.kexingbiopharm.com/reminton/apexelsin-paclitaxel-for-injection.html